ASCO 2025

De-escalating therapy - a step forward

WSG: HER2+ pooled analysis

Intraoperative dose escalation helps to reach targeted…

TRADE: Abemaciclib in eBC

HRD and BRCA status as a new innovative staging system?

Next-gen endocrine therapies and ADCs: Updates from…

SERENA-6 - a challenging strategy?

New compounds - new approaches: TNBC | HR+ | HER2+

AI and ADCs: Precision diagnostics & safer rechallenge…

SG + Pembro in aTNBC: a new standard of care?

A new standard for endocrine-resistant HR+ MBC?

Triple therapy 1st line | double therapy 2nd line - new…

Effective ADC for HER2+ mBC with brain metastases

New AKT/PIK3 Antagonist for treatment of mBC after…

Final OS-Analysis of INAVO-120 trial

Re-exposition and ILD

Vepdegestrant for treatment of ER+/HER2- aBC

Future new SOC for PD-L1-positive mTNBC

Liquid biopsy as a navigator for personalized therapy…

A new first-line therapy for TNBC

Additional ADC effective for untreated TNBC

ASCENT-04

Additional chemo-free option for TNBC

New firstline SOC for HER2+ metastatic BC

Sac-TMT for metastatic TNBC

SG + Pembrolizumab might become SOC for PD-L1-positive…

Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…

New SOC in first-line treatment for primary endocrine…

New treatment option in first line of metastatic TNBC

ABC for metastatic TNBC

Analisi finale della OS dello studio INAVO-120

Una nuova terapia di prima linea per il TNBC

SG + Pembrolizumab podría convertirse en el tratamiento…

Nuova opzione di trattamento in prima linea per il TNBC…

Un nouveau traitement de première ligne pour le TNBC

Nuovo antagonista di AKT/PIK3 per il trattamento della…

Vepdegestrant per il trattamento di ER+/HER2- aBC

PARP-inhibitor combinations in advanced prostate cancer

The role of ARPIs in mHSPCThe role of ARPIs in mHSPC

Localized CSPC - innovations

Immuntherapy - an evolution?

New way of treatment for PCa

Stereotactic beam radiation therapy 2.0

Personalized In Situ Immunotherapy SYNC-T Shows High…

Rebirth of Rucaparib

mHSPC - ADT + NHT updates

mHSPC - prognostification - indications on integration?

Adding EZH2 to Enzalutamide to decrease the development…

Combination of LU-PSMA and immunotherapy, EVOLUTION…

News of ANZUP trial

CAN-2409 Offers First New Option in 20 Years

MMAI Model identifies patients who benfit from ARPI in…

Real world data from ironman registry confirms…

Real-world data från Ironman: PSA nivå en viktig…

Evolution: Kombination av LuPSMA och immunterapi.

ICI Combos in 1L and Maintenance – Mixed Bags or…

ctDNA Clearance Confirms Added Value of Perioperative…

Complete but Not Finished: EV+P cCR Data Extend the SOC…

The role of sansalimab (+ SG) in BCG-naive and…

mUC EVP + subsequent therapies

UTUC - enlighted

Response matters in advanced urothelial cancer patients…

Intensive caution of BCG Therapy

mUC - new approaches?

NIAGARA study and circulating tumor DNA

ASCO 2025 - Highlights for Bladder Cancer

New nectin-4 ADCs are coming

A new prognostic factor in bladder cancer?: The case of…

Benefit of IO/IO therapy in mUC

New option for high-risk NMIBC

CREST Study: Promising Results with PD-1 Inhibitor…

HIF alfa sigue siendo una diana interesante en el RCC y…

¿Un nuevo factor pronóstico en el cáncer de vejiga? El…

El rol de sansalimab (+ SG) en el carcinoma urotelial…

La respuesta es importante en pacientes con cáncer…

De nouveaux ADC pour la nectine-4 arrivent

Casdatifan + Cabo – Too Early to Call It a Game…

9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…

PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions

Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…

Nivo + Ipi - Update & Insights

5-Year OS data from the KEYNOTE-564 study

HIF alpha still an interesting target in RCC and other…

Allogeneic CD70 CAR T Cells in refractory RCC

Long-term outcome of Nnivo-Ipi in clear cell RCC

New synergies? Radiotherapy and IO in Limited-Stage…

cTDNA in periop chemo-IO strategies

Neadjuvant targeted therapy

ctDNA stratification

Neoadjuvant Alectinib in resectable stage III NSCLC

Updates in perioperative strategies in NSCLC

Chemoimmunotherapy followed by chemoradiotherapy

CheckMate 816: Update on OS-benefit

CM-816: The OS results are positive and demonstrate…

Actualizaciones en estrategias perioperatorias en NSCLC

CM-816 : Les résultats de l'OS sont positifs et…

Targeting rare mutations in metastatic NSCLC - HER2 and…

What is the future in the field of EGFR resistance?

Have we MET our target?

Immunotherapy – before or after 3 p.m.?

KRAS G12C: Can immunotherapy improve patient outcome…

ADC in the 3L beats docetaxel

TROP2 targets – where is first-line development…

Does the timing of IO-infusion impact survival?

GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…

Sevarbertinib – an additional option for HER2 exon 20…

ADC as 3L in EGFR

Benefit of IO is depending on the time of day of…

RELA-104-biomarker-analysis

Time of day of immunotherapy is important

HERTHENA-Lung02 unfortunately negative study -…

Updates on ADCs in EGFR resistance

Is there still a place for HER3-DXd in advanced NSCLC?

Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?

KRAS G12C: Kan immunotherapie alleen het resultaat voor…

Actualizaciones sobre los ADC en la resistencia al EGFR

Hebben we ons doel gehaald?

New therapies to improve patient survival

DeLLphi-304: Dramatic change in 2L-treatment in SCLC

Taralatamb - the new SOC in 2L treatment

New maintenance therapy for SCLC

The first positive maintenance therapy in SCLC

DeLLphi-304 : Changement radical dans le traitement de…

LA HNSCC - New neoadjuvant SOC